199 related articles for article (PubMed ID: 24495353)
1. Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics.
Penrod NM; Moore JH
BMC Syst Biol; 2014 Feb; 8():12. PubMed ID: 24495353
[TBL] [Abstract][Full Text] [Related]
2. Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole.
Penrod NM; Moore JH
BMC Med Genomics; 2013; 6 Suppl 2(Suppl 2):S2. PubMed ID: 23819860
[TBL] [Abstract][Full Text] [Related]
3. Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity.
Penrod NM; Greene CS; Moore JH
Genome Med; 2014; 6(4):33. PubMed ID: 24944582
[TBL] [Abstract][Full Text] [Related]
4. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
5. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
6. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
9. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
10. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Balko JM; Mayer IA; Sanders ME; Miller TW; Kuba MG; Meszoely IM; Wagle N; Garraway LA; Arteaga CL
Mol Cancer Ther; 2012 Oct; 11(10):2301-5. PubMed ID: 22879364
[TBL] [Abstract][Full Text] [Related]
11. Letrozole for the management of breast cancer.
Goss PE; Smith RE
Expert Rev Anticancer Ther; 2002 Jun; 2(3):249-60. PubMed ID: 12113048
[TBL] [Abstract][Full Text] [Related]
12. Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Lu Y; You M; Ghazoui Z; Liu P; Vedell PT; Wen W; Bode AM; Grubbs CJ; Lubet RA
Cancer Prev Res (Phila); 2013 Nov; 6(11):1151-61. PubMed ID: 24067424
[TBL] [Abstract][Full Text] [Related]
13. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
14. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
15. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
16. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
18. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
[TBL] [Abstract][Full Text] [Related]
19. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
Chimge NO; Baniwal SK; Luo J; Coetzee S; Khalid O; Berman BP; Tripathy D; Ellis MJ; Frenkel B
Clin Cancer Res; 2012 Feb; 18(3):901-11. PubMed ID: 22147940
[TBL] [Abstract][Full Text] [Related]
20. CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma.
Jia X; Liu G; Cheng J; Shen Z; Shao Z
Curr Cancer Drug Targets; 2017; 17(2):191-197. PubMed ID: 27113745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
